Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Vicebio, a UK biotech startup based in London, has secured $100 million in Series B financing to develop cost-effective vaccines for respiratory viruses. The funding round was led by TCGX, Goldman Sachs Alternatives, Avoro, venBio, uniQuest, and Medicxi. The company announced today that it will initiate a Phase 1 clinical study of its RSV/hMPV bivalent vaccine. Vicebio aims to deliver vaccines that are highly effective, easy to manufacture, and ready-to-use in prefilled syringes.
We have led a $58M investment in Constructive Bio, the pioneering synthetic genomics company, in one of the largest UK biotech Series A rounds in recent years.
From Cambridge, UK: Synthetic biology company @BioConstructiv announced a $58 million series A today, one of the largest in the UK region. Full video: https://t.co/mAHaO6K5IE https://t.co/CNra6h9EXB
$LIPO provided an update on its Ph 2a clinical trial evaluating LP-310 to treat Oral Lichen Planus (OLP). Three participants completed the four-week treatment, which was well tolerated with no unpleasant taste. Read more👇 https://t.co/9uWZ4nmskm $SEEL $WVE $BIVI $CAPR $HSCS https://t.co/X6GOgq8aQQ